Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 17/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804601 | 0.88 | PDGFRB (0.47) | PDGFRBHTTRXFP1 | |
| SCHEMBL4202933 | 0.87 | KIT (0.47) | ADRB2ADRB1ADRB3PDGFRBKIT | |
| SCHEMBL4188891 | 0.86 | KIT (0.48) | ADRB2ADRB1ADRB3KIT | |
| SCHEMBL4195995 | 0.85 | MAOB (0.48) | ADRB2ADRB1ADRB3PDGFRBKIT | |
| SCHEMBL4193050 | 0.84 | KIT (0.47) | ADRB2ADRB1ADRB3KIT | |
| SCHEMBL4199203 | 0.84 | CA12 (0.55) | ADRB2ADRB1ADRB3PDGFRBKIT | |
| SCHEMBL4192589 | 0.83 | KIT (0.47) | ADRB2ADRB1ADRB3KIT | |
| SCHEMBL4198558 | 0.82 | ADRB2 (0.56) | ADRB2ADRB1ADRB3PDGFRBKIT | |
| SCHEMBL4198431 | 0.81 | KIT (0.52) | ADRB2ADRB1ADRB3PDGFRBKIT | |
| SCHEMBL4187288 | 0.80 | KIT (0.45) | ADRB2ADRB1ADRB3KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-25 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | GAUL MICHAEL DAVID | 2009-06-04 | — | — | US | disclosed |
| EP-1899355-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893215-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135639-A1 | THIΞNOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135630-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281768-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | ADRB2 3551/4885ADRB1 3249/4885ADRB3 3596/4885 |
| US-20090163710-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | ADRB2 3551/4885ADRB1 3249/4885ADRB3 3596/4885 |
| US-20090143378-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, CDK2 | ADRB2 3551/4885ADRB1 3249/4885ADRB3 3596/4885 |
| US-20060281769-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING THIENOPYRIMIDINE AND THIENOPYRIDINE KINASE MODULATORS | FLT3, TYMP, TPX2 | ADRB2 4517/4885ADRB1 4232/4885ADRB3 4211/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | ADRB2 4669/4885ADRB1 4628/4885ADRB3 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.